'Strengthening Anti-Cancer Leadership' Boryung and BigThink Therapeutics Jointly Market Breast Cancer Drug

Boryung announced on the 9th that it has signed a mutual co-promotion agreement with BigThink Therapeutics for two breast cancer treatments, aiming to strengthen its anticancer drug portfolio.

Through this agreement, the two companies will jointly engage in sales and marketing of BigThink Therapeutics' Neurings tablets and Boryung's Pulvet injection. They plan to expand their influence in the field of breast cancer through this collaboration.

Neurings is an oral epithelial growth factor receptor (HER2) positive breast cancer treatment developed by Puma Biotechnology in the United States. After receiving approval as an anticancer new drug from the U.S. Food and Drug Administration (FDA) in 2017, BigThink secured domestic distribution rights and introduced it in 2021. It is recommended as a treatment for early and metastatic breast cancer in the U.S. National Comprehensive Cancer Network (NCCN) guidelines. Notably, it is the first and only extended adjuvant therapy in Korea that can reduce the risk of recurrence and brain metastasis in HER2-positive early breast cancer.

Pulvet is a breast cancer treatment containing fulvestrant, launched by Boryung. It is a generic drug, with the original being AstraZeneca's Faslodex. It is used as monotherapy or combination therapy for hormone receptor-positive, HER2-negative, postmenopausal advanced and metastatic breast cancer.

With this agreement, Boryung explained that it has secured Neurings in addition to the already marketed Xeloda, Taxol, and Sampenet, thereby providing various treatment options for breast cancer patients. According to the Health Insurance Review & Assessment Service, the number of breast cancer patients in Korea last year was 290,000, making it the second most common cancer after thyroid cancer (410,000 patients).

Kim Young-seok, Executive Director and Head of Boryung's Oncology Division, said, “Through this cooperation between the two companies, Boryung can now offer comprehensive treatment options ranging from adjuvant therapy after surgery for early breast cancer patients to extended adjuvant therapy.” He added, “We will continue to actively secure portfolios to expand patients' treatment rights and do our best to improve treatment outcomes.”